Last reviewed · How we verify
VX-147
At a glance
| Generic name | VX-147 |
|---|---|
| Also known as | IXP |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease (PHASE2, PHASE3)
- Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities (PHASE2)
- Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis (PHASE2)
- Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment (PHASE1)
- A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment (PHASE1)
- A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VX-147 CI brief — competitive landscape report
- VX-147 updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI